The drivers of inflammation and lymphocytopenia in COVID-19 are not well understood yet, but the preliminary data generated to date by this and other [16], [13] studies suggest that interfering with IL-6 activity improves these indices. This evidence concerns the gene IL6 and lymphopenia.